LDS/Medical Tests/Buspirone Quantitative, Serum

Buspirone Quantitative, Serum

Buspirone is an azaspirodecanedione drug used primarily for its anxiolytic properties. Buspirone is very similar to benzodiazepines in its effect. However, unlike benzodiazepines and zolpidem, buspirone does not mediate its CNS-depressant activity through GABA receptors. The specific mechanism of action remains unknown, although the drug does interact with serotonergic (5-HT1A and 5-HT2) and dopaminergic (D2) receptors. Typical route of administration is oral. The major metabolites of buspirone are 6-hydroxybuspirone and 1-(-2pyrimidinyl) piperazine (1-PP), which are both pharmacologically active. The 1-PP metabolite is further metabolized by hydroxylation and may be conjugated. The half-life of buspirone varies between 3-12 hours but is typically less than 6 hours.

A single oral dose is primarily eliminated within 24 hours, with half or more appearing in the urine as metabolites. Actual elimination depends on factors such as drug formulation dose, dose frequency, clinical status and pharmacokinetics of the individual patient.

Common side effects: dizziness, drowsiness, light-headedness, headache, and nervousness. Overdose effects include nausea and vomiting, seizures, miosis, coma, and possible death.

Buspirone and metabolites are not widely monitored, but it can be detected in urine by a variety of analytical methods (see below); both qualitative and quantitative tests are available.

  • Adherence monitoring
  • Drug abuse evaluation
  • Toxicity/Overdose assessment
A qualitative positive result indicates only the presence of Buspirone and does not necessarily correlate with the extent of physiological and psychological effects, nor does it predict the dose that was taken or administered. Any result that is inconsistent with clinical expectations should be confirmed or quantitated by a second method.

Therapeutic levels: <0.01 mg/L

Toxic levels: Data not available 

Note: therapeutic ranges and toxic thresholds are best evaluated from blood samples. Quantitative results obtained with blood samples collected at specific times after drug administration are preferred for pharmacokinetic analyses.  

    

Cut-Off Ranges

Cut-off values are used to determine the positivity of the urine specimen being analyzed. Cut-off values can vary based on the particular method of analysis that is used for detection, whether the test is a qualitative method or a quantitative method. Detection will be improved with low cutoff concentrations. The testing laboratory cut-off range is listed on the patient report.

Many are possible, including Liquid Chromatography/Mass Spectroscopy (LC/MS, LC-MS/MS), Gas Chromatography/Mass Spectroscopy (GC/MS), or Thin Layer Chromatography (TLC). Immunoassays (IA) specific for buspirone are not available. Laboratories may include a pre-analytical hydrolysis reaction to liberate the glucuronide conjugates, which may improve detection.

Serum (SST). 

Stability

  • Ambient: 5 days
  • Refrigeration: 7 days
  • Frozen: 30 days
Pharmacogenetic testing such as genotyping for *CYP3A4, CYP3A5, CYP2D6, CYP2C9,* and *CYP2C19* variants could guide drug and dose selection. Supportive testing such as a liver profile, kidney profile, comprehensive metabolic panel, CBC, and testing for concomitant drugs may be appropriate.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 9th ed. Seal Beach, CA: Biomedical Publications; 2011.
  • Mead Johnson, Pharmaceuticals. Buspar (buspironehydrochloride) prescribing information. Princeton, NJ; 2002Feb.